Seqirus
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Seqirus sits in the top decile of US sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count).
Seqirus: 25 sponsored US clinical trials, none currently recruiting.
Seqirus sponsors 25 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 24 completed. 14 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Influenza, Human, with 4 trials.
Top-decile sponsor footprint
Seqirus ranks in the top decile of sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
24 of 24 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
25 total, page 1 of 1
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
NCT06087640
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older
NCT06015282
Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults
NCT05875961
Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults
NCT05874713
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age
NCT05501561
A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed
NCT05422326
A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age
NCT05044195
Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults
NCT04576702
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
NCT04074928
Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
NCT03314662
Afluria Pregnancy Registry
NCT03442582
Flucelvax (TIVc or QIVc) Pregnancy Registry
NCT03438487
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
NCT02914275
A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
NCT02839330
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age
NCT02545543
Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05
NCT02255409
A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years
NCT02212106
A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.
NCT02214225
Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old
NCT02035696
Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
NCT01964989
A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population
NCT00959049
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA
NCT00958126
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA
NCT00958243
Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)
NCT00812019
A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine
NCT00735475
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 3 | 12 |
| Phase 4 | 2 |
Therapeutic Areas
How the Seqirus archive is shaped
25 indexed studies, none listed as recruiting (0% open); 24 completed (96%).
Phase mix: 14 late (III/IV) vs 9 early (I/II) (later-stage heavy).
Top condition: Influenza, Human (4 trials), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Seqirus: archived-pipeline peers nationwide
Peers matched on 25 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Seqirus sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 25 archived trials
- Arcus Biosciences · 25 trials · 12% recruiting
- Arcutis Biotherapeutics · 25 trials · 8% recruiting
- Ardelyx · 25 trials · 12% recruiting
- Drexel University College of Medicine · 25 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Seqirus page
25 registered trials is a research-attention snapshot, not an endorsement of Seqirus or any single study.
- None of Seqirus's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Influenza, Human is the condition Seqirus studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Influenza, Human trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Seqirus pipeline card: 25 registered trials from official public datasets.Report a data error.